Market research
MNPR Monopar Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 744M
- P/E ratio
- Not available
- Analyst target
- 126.3077
- Dividend yield
- Not available
- Beta
- 1.51
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US61023L2079
- Market cap
- 744M
- P/E ratio
- Not available
- Analyst target
- 126.3077
- Dividend yield
- Not available
- Beta
- 1.51
About
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MNPR discussion.
5 years, 4 months ago
Monopar Therapeutics Inc is currently in a long term downtrend where the price is trading 7.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Monopar Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 522395059.7% to $-6T since the same quarter in the previous year.
Finally, its free cash flow fell by 85.5% to $-1M since the same quarter in the previous year.
Based on the above factors, Monopar Therapeutics Inc gets an overall score of 1/5.